Ocular Hypertension Market Set to Grow Through 2036 as Sustained-Release Implants and Novel Mechanisms Reshape Treatment | DelveInsight

DelveInsight's "Ocular Hypertension Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of ocular hypertension, historical and forecasted epidemiology, as well as the ocular hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Ocular Hypertension Market Report @ https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Ocular Hypertension Market Report
• In May 2026, Ocuvex Therapeutics received a Complete Response Letter (CRL) from the US FDA pertaining to the New Drug Application (NDA) for PDP-716, a novel once-daily ophthalmic suspension intended for the treatment of glaucoma.
• In February 2026, Nicox highlighted positive NCX 470 Phase III data confirming its therapeutic profile at the 2026 American Glaucoma Society Annual Meeting, demonstrating best-in-class IOP-lowering efficacy of up to 10 mmHg from baseline, meeting NDA efficacy requirements in the US and China.
• In February 2026, Nicox announced that it received positive written feedback from its NCX 470 pre-NDA meeting with the US FDA.
• Among EU4 and the UK, Germany accounted for the highest number of cases, whereas Spain accounted for the least number of cases in 2025.
• Japan accounted for approximately 20% of prevalent cases of ocular hypertension among the 7MM.
• Females are more affected than males with ocular hypertension.
• In France, the prevalence of glaucoma and ocular hypertension in the population over 40 has been estimated at 4.1%, or 1.2 million people.
• Age older than 40 years is considered a risk factor for the development of ocular hypertension and primary open-angle glaucoma (POAG).
• Since there are no early signs and symptoms for ocular hypertension, the disease often goes unnoticed until it progresses to glaucoma.
• The Ocular Hypertension Companies include Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company (SPARC), Visiox Pharma, Ono Pharmaceutical, and others.
• Promising Ocular Hypertension Therapies include NCX 470, PDP-716, Sepetaprost (DE-126/ONO-9054/STN1012600), and others.

Get a Free sample for the Ocular Hypertension Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Ocular Hypertension?
Ocular hypertension is a condition in which intraocular pressure (IOP) is elevated without optic nerve damage or vision loss associated with glaucoma. It results from impaired drainage of aqueous humor, increasing pressure inside the eye. Adults over 40 are at greater risk. Although often symptom-free, untreated ocular hypertension can progress to primary open-angle glaucoma. Diagnosis includes tonometry, pachymetry, gonioscopy, optic nerve evaluation, optical coherence tomography (OCT), and visual field testing.

Ocular Hypertension Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Ocular Hypertension
• Gender-specific Cases of Ocular Hypertension
• Age-specific Cases of Ocular Hypertension
• Treated Cases of Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Ocular Hypertension Approved Therapies
• Travoprost Intracameral Implant (iDose TR): Glaukos
iDose TR is a first-of-its-kind, long-duration, anchored intracameral procedural pharmaceutical therapy designed to continuously (24/7) deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. It is indicated for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension and is composed of a biocompatible intracameral implant preloaded in a sterile, single-dose inserter. It was approved in the US in 2023.

• Omidenepag Isopropyl Ophthalmic Solution (OMLONTI): Santen and UBE Corporation
OMLONTI is a novel ophthalmic therapy approved for the reduction of elevated IOP in patients with OAG and ocular hypertension. It contains omidenepag isopropyl, a selective prostaglandin E2 (EP2) receptor agonist that lowers IOP by enhancing both trabecular and uveoscleral aqueous humor outflow pathways, and is the first approved therapy with this unique mechanism. FDA approval was based on data from 12 clinical studies; a US Phase III study confirmed non-inferiority to timolol, while two separate Phase III studies in Japan and Asia showed non-inferiority to latanoprost. It is administered as a once-daily ophthalmic solution (0.002%), typically dosed in the evening, and was approved in the US in 2022.

• Bimatoprost Implant (DURYSTA): Allergan
DURYSTA is a prostaglandin analog intracameral implant approved in the US in 2020 for ocular hypertension.

Ocular Hypertension Pipeline Analysis
• NCX 470: Nicox Ophthalmics
NCX 470 is Nicox's lead clinical asset, an investigational nitric oxide-donating bimatoprost ophthalmic solution being developed for OAG and ocular hypertension. It combines bimatoprost with nitric oxide-mediated trabecular meshwork relaxation to enhance aqueous humor outflow and improve IOP reduction versus conventional prostaglandin analogs like latanoprost. In Phase III trials, including Mont Blanc and Denali, NCX 470 demonstrated non-inferior and numerically superior IOP lowering versus latanoprost at multiple timepoints while maintaining a favorable tolerability profile. The drug completed Phase III trials with topline results reported in August 2025, and the company anticipates submitting its NDA in 2026.

• PDP-716: Sun Pharma Advanced Research Company (SPARC)/Ocuvex Therapeutics
PDP-716 is an investigational once-daily ophthalmic suspension of brimonidine tartrate 0.35% being developed for OAG and ocular hypertension, using SPARC's proprietary TearAct technology for sustained drug delivery and improved bioavailability, enabling once-daily dosing versus currently marketed brimonidine formulations requiring three-times-daily administration. In a pivotal Phase III trial, PDP-716 met its primary endpoint, demonstrating IOP reduction comparable to Alphagan P 0.1% dosed three times daily, with a similar safety profile. It was licensed by SPARC to Visiox Pharmaceuticals in 2021 for global rights outside India and Greater China; Visiox merged with Ocuvex Therapeutics in 2024.
• Sepetaprost (DE-126/ONO-9054/STN1012600): Santen/Ono Pharmaceutical
Sepetaprost is an EP3 receptor agonist and Prostaglandin F2 alpha agonist in Phase II development for ocular hypertension.

Discover more about therapies set to grab major Ocular Hypertension market share @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Ocular Hypertension Companies
Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company, Visiox Pharma, Ono Pharmaceutical, and others

Ocular Hypertension Market Outlook
The treatment landscape for ocular hypertension has evolved significantly from conventional topical IOP-lowering therapies toward long-acting implants and novel mechanism-based agents aimed at improving efficacy, durability, and patient adherence. Approved therapies such as travoprost intracameral implant (iDose TR), omidenepag isopropyl ophthalmic solution (OMLONTI), and bimatoprost implant represent important advancements in sustained drug delivery and alternative prostaglandin receptor targeting, addressing unmet needs associated with poor adherence to daily eye drops and fluctuations in IOP control.
Investigational candidates such as NCX 470, PDP-716, and Sepetaprost are being developed to provide superior IOP reduction, improved tolerability, and longer duration of action compared with currently available therapies. However, the regulatory pathway for PDP-716 has encountered setbacks: the US FDA issued a Complete Response Letter for its NDA in July 2023 due to unresolved facility inspection-related observations at a third-party API manufacturing site, rather than concerns over safety or efficacy. SPARC and Ocuvex Therapeutics resubmitted the NDA in late 2025, but the FDA issued another CRL in May 2026, potentially extending approval and launch timelines.
Overall, the ocular hypertension market across the 7MM is expected to witness steady growth from 2026 to 2036, driven by increasing disease prevalence, aging populations, improved screening rates, and continued innovation in ophthalmic therapeutics, with growing adoption of sustained-release implants, minimally invasive treatment approaches, and differentiated topical therapies anticipated to reshape the competitive landscape.

Scope of the Ocular Hypertension Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM (US, EU4 [Germany, France, Italy, Spain], UK, Japan)
• Ocular Hypertension Companies: Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company, Visiox Pharma, Ono Pharmaceutical, and others
• Ocular Hypertension Therapies: Travoprost intracameral implant (iDose TR), Omidenepag isopropyl ophthalmic solution (OMLONTI), Bimatoprost implant (DURYSTA), NCX 470, PDP-716, Sepetaprost (DE-126/ONO-9054/STN1012600), and others
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Ocular Hypertension Unmet Needs, KOL's views, Analyst's views, Ocular Hypertension Market Access and Reimbursement

To know more about Ocular Hypertension companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of Ocular Hypertension
6. Ocular Hypertension Market Overview at a Glance
7. Disease Background and Overview of Ocular Hypertension
8. Epidemiology and Patient Population of Ocular Hypertension
9. Patient Journey of Ocular Hypertension
10. Marketed Therapies
11. Emerging Therapies
12. Ocular Hypertension: Seven Major Market Analysis
13. Unmet Needs of Ocular Hypertension
14. SWOT Analysis of Ocular Hypertension
15. KOL Views of Ocular Hypertension
16. Market Access and Reimbursement of Ocular Hypertension
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.